



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/116617/>

Version: Accepted Version

Article:

Nikolaou, VS and Giannoudis, PV (2017) History of osteochondral allograft transplantation. *Injury*, 48 (7). pp. 1283-1286. ISSN: 0020-1383

<https://doi.org/10.1016/j.injury.2017.05.005>

© 2017 Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Accepted Manuscript

Title: History of osteochondral allograft transplantation


Authors: V.S Nikolaou, P.V Giannoudis

PII: S0020-1383(17)30327-3

DOI: <http://dx.doi.org/doi:10.1016/j.injury.2017.05.005>

Reference: JINJ 7231

To appear in: *Injury, Int. J. Care Injured*



Please cite this article as: Nikolaou VS, Giannoudis P.V. History of osteochondral allograft transplantation. *Injury* <http://dx.doi.org/10.1016/j.injury.2017.05.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

History of osteochondral allograft transplantation

V.S Nikolaou¹ and P.V Giannoudis^{2,3}

Vasileios S. Nikolaou MD

¹Assistant Professor of Orthopaedics
²Orthopaedic Department
School of Medicine
National & Kapodistrian University of Athens
Greece

Peter V Giannoudis MD, FACS, FRCS

²Professor and Chairman, Academic Department
of Trauma & Orthopaedics, School of
Medicine, University of Leeds

³ NIHR, Leeds Musculoskeletal Biomedical
Research Center, Chapel Allerton Hospital, Leeds, UK

CORRESPONDENCE TO:

Professor P V Giannoudis BSc, MB, MD, FACS, FRCS
Department of Trauma and Orthopaedics
Academic Unit, Clarendon Wing
Leeds Teaching Hospitals NHS Trust
Great George Street, Leeds, LS1 3EX,
United Kingdom
Tel: 0113-3922750
Email: pgiannoudi@aol.com

Abstract

Osteochondral defects or injuries represent the most challenging entities to treat, especially when occur to young and active patients. For centuries, it has been recognized that such defects are almost impossible to treat. However, surgeons have never stopped the effort to develop reliable methods to restore articular cartilage and salvage the endangered joint function. Osteochondral

allograft transplantation in human was first introduced by Eric Lexer in 1908. Since that era, several pioneers have been worked in the field of osteochondral allotransplantation, presenting and developing the basic research, the methodology and the surgical techniques. Herein we present in brief, the history and the early clinical results of osteochondral allograft transplantation in human.

KeyWords: Osteochondra; transplantation; Allograft; history;

Osteochondral defects or injuries represent the most challenging entities to treat, especially when occur to young and active patients. Such lesions involve the articular cartilage and the subchondral bone. For centuries, it has been recognized that such defects are almost impossible to treat. Back in 1743, William Hunter (1718-1783) stated that *“from Hippocrates down to the present age, ulcerated cartilage is a troublesome disease; when destroyed, it is not recovered”* [1, 2] (**Figure 1**). Almost 100 years later, in 1851, Sir James Paget wrote, *“There are, I believe, no instances in which a lost portion of cartilage has been restored, or a wounded portion repaired, with new and well-formed permanent cartilage, in the human subject.”* [3]. Since that era, tremendous effort has been made by orthopaedic surgeons to develop reliable methods to restore articular cartilage and salvage the endangered joint function.

Both mechanical or biological methods have been developed for the treatment of the symptomatic osteochondral lesions. Osteotomies, arthroplasty, micro-fractures, abrasion arthroscopy, mosaic-plasty and autologous chondrocyte transplantation techniques are currently used as treatment options. However, each method has limitations. Arthroplasty is generally not recommended for young active patients due to the risk of early failure or infection. Microfractures and abrasion arthroscopy leads to the formation of fibrocartilage or mixed hyaline and fibrocartilage. Mosaic-plasty has the limitation of donor site morbidity and autologous chondrocyte transplantation demands two operations and is an expensive procedure. Even more importantly, all these methods are generally limited to defects less than 2-3 cm² and 1-2 cm deep [4-6].

On the other hand, fresh osteochondral allograft transplantation involves the transfer of size-matched allograft cartilage and subchondral bone into chondral or osteochondral defects. This method not only restores true type II hyaline cartilage but also directly address any associated bone defects. The nature of allograft chondral tissue is ideal for transplantation as it is avascular and

aneural tissue. Moreover, studies have shown that it is also relatively immunologically inactive and privileged, as the chondrocytes are embedded in the extracellular matrix [7].

Henri Judet, first reported the implantation of osteochondral grafts in animals [8] but the clinical use of allograft joint transplants was first introduced by Lexer in 1908. Eric Lexer (**Figure 2**) was born in Freiburg, Germany in 1867. He graduated medical school in Wurzburg in 1890 and he received his surgical training in Berlin. He was appointed Professor of surgery in Konigsberg, Jena, Freiburg and finally Munich in 1928. He died in 1937, leaving a tremendous amount of work in the fields of anatomy, bone infections and tissue transplantations. In the clinical setting, he was famous as a general and plastic surgeon [9].

Lexer published his early experience with “joint allotransplantation” by three different methods; half joint replacement, both articular surfaces replacement and total joint transplantation, including joint capsule. The first case to present was a 38 years old male with proximal tibia sarcoma. The affected part of patient’s proximal tibia was surgically removed and replaced by a proximal tibia osteochondral allograft. The allograft was taken, in a synchronous way, by a man whose leg was amputated due to gangrene. At the 8 month follow up, Lexer evaluated the outcome of this procedure as excellent. Interestingly, he described the procedures of allotransplantation of half joints and even total joints with good and fair results. All transplants were obtained by fresh amputated legs at the same day of surgery. However, he acknowledged that joint transplantation is not an easy procedure and that he was not able to promise successful and permanent results [10]. By 1925, Lexer had documented 34 hemi or whole knee allogenic implants in humans and reported a 50% success rate. [11]

The following years a few more case reports [12, 13] had been published but the interest on osteochondral allograft transplantation remained limited, until the early 1970’s, when early reports of large series appeared. Volcov, from the Central Institute of Traumatology and Orthopaedics in Moscow, published in 1970 a series of 145 operations of joint allotransplantation. He reported four groups of operations; focal osteochondral transplantation, one joint surface with its supporting bone replacement, two joint surfaces replacement and whole joint complex replacement [14]. In most of the cases allografts harvested by persons that have died by injury or myocardial infraction, were preserved by freezing in -70 °C for 24 hours, followed by storage at -30 °C. Volcov reported good results in all fifteen cases of partial joint replacement and 60% good

results in patients with half joint replacement. In fifteen cases with total joint allotransplantations he reported inferior results eighteen months after transplantation [14].

Approximately at the same period, Ottolenghi [15] and Parrish [16] published their experience with osteochondral allograft transplantation. In 1972, Carlos Ottolenghi presented the results of 62 patients with osteoarticular or metadiaphyseal bone allograft transplantation. From these patients 16 received osteoarticular transplant, mainly due to bone tumor resection. All grafts were obtained from dead people due to accidents or from amputated extremities of patients with congenital defects. The grafts were removed within 6 hours of death, under sterile conditions, and were stored in sterile boxes or bottles. Then, they were presented in freeze of $-15\text{ }^{\circ}\text{C}$ to $-25\text{ }^{\circ}\text{C}$. All grafts were used within 6 months of harvesting. Before implantation grafts were thawed in a solution of penicillin for 30-60 mins. Overall 59% of patients had finally good results. Interestingly, Ottolenghi reported that in cases of osteoarticular allografts, results were good, (good range of joint motion and pain-free) even in cases that there were signs of graft absorption and necrosis [15].

Similarly, in 1973, Frank Parrish, from Texas published the results of massive osteochondral allograft transplantation in patients with tumor of the end of long bone [16]. Overall, 22 massive allografts were transplanted in 21 patients. Eleven patients had total and five partial replacements of different large joints, including the distal femur, the distal and proximal end of the tibia and the proximal end of humerus. The grafts were removed from adult donors, whose cause of death was trauma or heart disease. The osteochondral grafts were harvested within the first twelve to eighteen hours after the death of the donor, under usual sterile conditions. Cultures were taken and grafts were stored in $-20\text{ }^{\circ}\text{C}$ for at least three weeks. Twenty-four hours before transplantation, the grafts were removed from deep freeze and were submerged in solution containing neomycin and bacitracin and kept in ordinary refrigeration temperature. Parrish reported that at the latest follow-up, sixteen patients still had their limbs, three had amputations and one was lost to follow-up. The clinical results and functional status of patients varied extensively but he did mention that these results appeared to justify continuation of the osteochondral allograft transplantation procedure [16].

The revived interest in osteochondral allograft transplantation that was observed in the late 60's and early 70's can be attributed to the better understanding of the grafts immunogenicity and

the optimal methods of preservation and storage. Early experimental studies by Paul Curtiss [17-19], and Herndon [20], effectively showed that freezing the cadaveric bony parts reduce immunological activity and thus reduce the rejection rate. Fred Langer and co-workers from Canada, have also shown that a blocking antibody was produced by the temperature reduction [21]. Also Langer and Gross, in 1974 concluded that chondrocytes are relatively immunoprivileged, as the surrounding matrix protects them from the immunocompetent cells assault [7]. On the other hand, also early studies have shown that preservation of the grafts by freezing cause chondrocyte death in 90% to 50%, depending on the freezing methods [22]. Thus, different centers, mainly in North America and elsewhere have started to use different methods of cryopreservation of osteochondral allografts with mixed results. Generally, the standards for grafts cryopreservation have been established at either -70 to -80 °C for frozen grafts or 4 °C for “fresh” grafts. Additionally, Ringer’s lactate or cryoprotectants, such as ethylene glycol, dimethyl sulfoxide or glycerol were used during the freezing process to minimize chondrocyte death. At the same time the first bone banks were developed [23] and relatively large series with the first results in humans have started to be published.

Allan Gross has been a pioneer in the use of osteochondral transplantation for traumatic defects of the hip and knee. Gross and co-workers published in 1975 the first results of allotransplantation of osteochondral allografts in the treatment of knee osteoarthritis in eight patients [24]. Grafts were harvested within 24 hours of the donor’s death and were stored in Normasol M with Gentamycin and cephaloridine at 4 °C until implantation. They reported the early follow-up from 6 months to 2 years post-surgery. Results were very encouraging, as there was no rejection, all patients were fully ambulatory and developed good functional range of movement. In one patient they performed histological testing that revealed cartilage viability at 14 months [24].

Few years later, the same group published the results of 110 osteochondral transplants in patients with deficits due to degeneration, trauma, and neoplasm, mainly involving the knee joint [23]. They have used fresh grafts stored at 4 °C in Normosol M with cefazolin and gentamycin or frozen grafts stored at -70 °C. Fresh grafts were used within 24 hours from harvesting. They analyzed results of small fragment grafts (mainly fresh) and large fragment grafts (fresh or frozen). Overall, they reported 78 small fragment grafts and 32 large fragment grafts. Interestingly they reported that graft success depended more on the fate of bone than that of the cartilage, meaning

that if the bony part of the graft was compressed or fragmented, instability and malalignment occurred and the donor cartilage could be replaced by host fibrocartilage. Grafts with better results were those done for plateau fractures, trauma and giant cell tumors [23].

Beaver and co-workers, from the same center in Canada, reported the survivorship analysis of fresh osteochondral allografts of the knee in 98 patients (99 knees) [25]. In this series, donors were chosen to be less than 30 years old, to maximize cartilage quality. Grafts were harvested within 24 hours of death and when possible within 12 hours. Storage was made in antibiotic containing sterile Ringer's solution and temperature of 4 °C. The mean follow-up time was 68 months. Survival analysis showed that at five, ten and fourteen years after transplantation, the clinical success rate was 75%, 64% and 64% respectively. Authors analyzed that clinical success depended more upon biomechanical factors than upon graft rejection. Additionally, they stated that for the long term survival of the fresh allograft, there are three prerequisites; firstly the transplanted chondrocytes must remain viable. Secondly chondrocytes must continue to produce sufficient proteoglycan and collagen and thirdly the subchondral bone must be preserved [25].

Marvin Meyers and co-workers from Texas, presented their experience with fresh osteochondral allograft transplantation in 20 (21 hips) relatively young patients suffering from segmental collapse, in osteonecrosis of the hip [26]. Donors were 16-40 years old and the whole femoral head graft was harvested within 12 hours from death. Allografts were placed in antibiotics containing Ringer's solution and stored in 4 °C for up to 72 hours. Authors reported that 15 of the 21 hips had successful results. Nine patients had more than 18 months follow-up, five more than two years and two five years follow-up. The overall success rate was 71%. Patients with steroid induced avascular necrosis did worst [26].

John Garrett, also published the early results of osteochondral transplantation in 24 patients, suffering from osteochondral defects of a femoral condyle [27]. He has used fresh allografts from young donors. Transplantation was done within 12 hours from harvesting. The follow-up time was between 1 and 4 years. Garrett reported good results, as all patients improved at the latest follow-up. He was able to arthroscopically evaluate 11 allografts and concluded that in all cases graft appeared viable [27].

These are some of the earliest follow-up studies, demonstrating good to excellent clinical results of osteochondral allograft transplantation, mainly in the fields of hip and knee surgery.

Following these encouraging results research efforts have been intensified and better methods of allograft harvesting, handling, preservation and implantation have been presented [28-30]. Use of osteochondral allografts has been expanded to almost all the fields of orthopaedic surgery, including the patellofemoral joint [31], foot and ankle [32, 33] and shoulder and elbow [34-36] surgery. Long follow-up studies have recently been published confirming excellent long-term graft survival [37-39].

There is no doubt that as research continues in several areas, results will further be improved. Surgical techniques will be simplified and better tissue banking networking will allow a greater number of osteochondral allografts to become available for patients. Thus the “miracle” performed by Saints Cosmas and Damian, at the sixth century AD [40], known as “The miracle of the black leg” (**Figure 3**), will come as close to reality as ever.

Conflict of Interest: The authors declare no conflict of interest

References

- [1] Hunter W. Of the structure and disease of articulating cartilages. 1743. *Clin Orthop Relat Res.* 1995;3-6.
- [2] Hunter W. Of the structure and diseases of articular cartilages. . *Phil Trans* 1744;1744:514-21.
- [3] Paget J. The classics. II. Healing of cartilage. Sir James Paget, Bart, M.D., London, member of the RYAL Society. *Clin Orthop Relat Res.* 1969;64:7-8.
- [4] Richter DL, Schenck RC, Jr., Wascher DC, Treme G. Knee Articular Cartilage Repair and Restoration Techniques: A Review of the Literature. *Sports Health.* 2016;8:153-60.
- [5] Moran CJ, Pascual-Garrido C, Chubinskaya S, Potter HG, Warren RF, Cole BJ, et al. Restoration of articular cartilage. *J Bone Joint Surg Am.* 2014;96:336-44.
- [6] Farr J, Cole B, Dhawan A, Kercher J, Sherman S. Clinical cartilage restoration: evolution and overview. *Clin Orthop Relat Res.* 2011;469:2696-705.
- [7] Langer F, Gross AE. Immunogenicity of allograft articular cartilage. *J Bone Joint Surg Am.* 1974;56:297-304.
- [8] Judet H. Essai sur la greffe des tissus articulars. *Comp Rend Acad d Sciences.* 1908:193-6; 600-3,.
- [9] May H. The bibliography of Erich LEXER's scientific work. *Plast Reconstr Surg Transplant Bull.* 1962;30:670-5.
- [10] Lexer E. Ueber gelenktransplantation. *Med Klin.* 1908;4.
- [11] Lexer E. Joint transplantation and arthroplasty. *Surg Gynecol Obstet* 1925:782-9.
- [12] May H. The Regeneration of Joint Transplants and Intracapsular Fragments. *Ann Surg.* 1942;116:297-310.
- [13] Capurro RG, Pedemonte PV. Hydatid cysts of the femur; total removal of the femur and replacement by a complete cadaveric femur. *J Bone Joint Surg Br.* 1953;35-B:84-8.
- [14] Volkov M. Allotransplantation of joints. *J Bone Joint Surg Br.* 1970;52:49-53.
- [15] Ottolenghi CE. Massive osteo and osteo-articular bone grafts. Technic and results of 62 cases. *Clin Orthop Relat Res.* 1972;87:156-64.
- [16] Parrish FF. Allograft replacement of all or part of the end of a long bone following excision of a tumor. *J Bone Joint Surg Am.* 1973;55:1-22.
- [17] Curtiss PH, Jr., Powell AE, Herndon CH. Immunological factors in homogenous-bone transplantation. II. The inability of homogenous rabbit bone to induce circulating antibodies in rabbits. *J Bone Joint Surg Am.* 1959;41-A:1482-8.
- [18] Curtiss PH, Jr., Chase SW, Herndon CH. Immunological factors in homogenous-bone transplantation. II. Histological studies. *J Bone Joint Surg Am.* 1956;38-A:324-8; passim.
- [19] Curtiss PH, Jr., Herndon CH. Immunological factors in homogenous-bone transplantation. I. Serological studies. *J Bone Joint Surg Am.* 1956;38-A:103-10.
- [20] Herndon CH, Chase SW. The fate of massive autogenous and homogenous bone grafts including articular surfaces. *Surg Gynecol Obstet.* 1954;98:273-90.
- [21] Langer F, Gross AE, West M, Urovitz EP. The immunogenicity of allograft knee joint transplants. *Clin Orthop Relat Res.* 1978:155-62.
- [22] Tomford WW, Fredericks GR, Mankin HJ. Studies on cryopreservation of articular cartilage chondrocytes. *J Bone Joint Surg Am.* 1984;66:253-9.

- [23] Gross AE, McKee NH, Pritzker KP, Langer F. Reconstruction of skeletal deficits at the knee. A comprehensive osteochondral transplant program. *Clin Orthop Relat Res.* 1983;96-106.
- [24] Gross AE, Silverstein EA, Falk J, Falk R, Langer F. The allotransplantation of partial joints in the treatment of osteoarthritis of the knee. *Clin Orthop Relat Res.* 1975:7-14.
- [25] Beaver RJ, Mahomed M, Backstein D, Davis A, Zukor DJ, Gross AE. Fresh osteochondral allografts for post-traumatic defects in the knee. A survivorship analysis. *J Bone Joint Surg Br.* 1992;74:105-10.
- [26] Meyers MH, Jones RE, Bucholz RW, Wenger DR. Fresh autogenous grafts and osteochondral allografts for the treatment of segmental collapse in osteonecrosis of the hip. *Clin Orthop Relat Res.* 1983:107-12.
- [27] Garrett JC. Treatment of osteochondral defects of the distal femur with fresh osteochondral allografts: a preliminary report. *Arthroscopy.* 1986;2:222-6.
- [28] Cook JL, Stoker AM, Stannard JP, Kuroki K, Cook CR, Pfeiffer FM, et al. A novel system improves preservation of osteochondral allografts. *Clin Orthop Relat Res.* 2014;472:3404-14.
- [29] Garrity JT, Stoker AM, Sims HJ, Cook JL. Improved osteochondral allograft preservation using serum-free media at body temperature. *Am J Sports Med.* 2012;40:2542-8.
- [30] De Caro F, Bisicchia S, Amendola A, Ding L. Large fresh osteochondral allografts of the knee: a systematic clinical and basic science review of the literature. *Arthroscopy.* 2015;31:757-65.
- [31] Jamali AA, Emmerson BC, Chung C, Convery FR, Bugbee WD. Fresh osteochondral allografts: results in the patellofemoral joint. *Clin Orthop Relat Res.* 2005:176-85.
- [32] VanTinderen RJ, Dunn JC, Kusnezov N, Orr JD. Osteochondral Allograft Transfer for Treatment of Osteochondral Lesions of the Talus: A Systematic Review. *Arthroscopy.* 2017;33:217-22.
- [33] Schoenfeld AJ, Leeson MC, Grossman JP. Fresh-frozen osteochondral allograft reconstruction of a giant cell tumor of the talus. *J Foot Ankle Surg.* 2007;46:144-8.
- [34] Capito NM, Owens BD, Sherman SL, Smith MJ. Osteochondral Allografts in Shoulder Surgical Procedures. *JBJS Rev.* 2016;4.
- [35] Bellato E, Rotini R, Marinelli A, Guerra E, O'Driscoll SW. Coronoid reconstruction with an osteochondral radial head graft. *J Shoulder Elbow Surg.* 2016;25:2071-7.
- [36] van Riet RP, Morrey BF, O'Driscoll SW. Use of osteochondral bone graft in coronoid fractures. *J Shoulder Elbow Surg.* 2005;14:519-23.
- [37] Raz G, Safir OA, Backstein DJ, Lee PT, Gross AE. Distal Femoral Fresh Osteochondral Allografts: Follow-up at a Mean of Twenty-two Years. *J Bone Joint Surg Am.* 2014;96:1101-7.
- [38] Assenmacher AT, Pareek A, Reardon PJ, Macalena JA, Stuart MJ, Krych AJ. Long-term Outcomes After Osteochondral Allograft: A Systematic Review at Long-term Follow-up of 12.3 Years. *Arthroscopy.* 2016;32:2160-8.
- [39] Gross AE, Kim W, Las Heras F, Backstein D, Safir O, Pritzker KP. Fresh osteochondral allografts for posttraumatic knee defects: long-term followup. *Clin Orthop Relat Res.* 2008;466:1863-70.
- [40] Rinaldi E. The first homoplastic limb transplant according to the legend of Saint Cosmas and Saint Damian. *Ital J Orthop Traumatol.* 1987;13:393-406.



Figure 1: William Hunter (1718–1783).



Figure 2: Dr. Erich Lexer (1867–1937)



Figure 3: Spanish altarpiece of Saints Cosmas and Damian, performing the miracle of transplanting a leg (the miracle of black leg).